CN103327976A - 基于缺氧状态预选受试者以用于治疗性治疗 - Google Patents

基于缺氧状态预选受试者以用于治疗性治疗 Download PDF

Info

Publication number
CN103327976A
CN103327976A CN2011800653411A CN201180065341A CN103327976A CN 103327976 A CN103327976 A CN 103327976A CN 2011800653411 A CN2011800653411 A CN 2011800653411A CN 201180065341 A CN201180065341 A CN 201180065341A CN 103327976 A CN103327976 A CN 103327976A
Authority
CN
China
Prior art keywords
cancer
ldh
hypoxia
level
ldh5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800653411A
Other languages
English (en)
Chinese (zh)
Inventor
R.K.布莱克曼
V.乌科维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of CN103327976A publication Critical patent/CN103327976A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2011800653411A 2010-11-18 2011-11-18 基于缺氧状态预选受试者以用于治疗性治疗 Pending CN103327976A (zh)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US41514710P 2010-11-18 2010-11-18
US41513610P 2010-11-18 2010-11-18
US41513910P 2010-11-18 2010-11-18
US41512210P 2010-11-18 2010-11-18
US41515610P 2010-11-18 2010-11-18
US41515510P 2010-11-18 2010-11-18
US41515810P 2010-11-18 2010-11-18
US61/415,139 2010-11-18
US61/415,156 2010-11-18
US61/415,147 2010-11-18
US61/415,122 2010-11-18
US61/415,155 2010-11-18
US61/415,158 2010-11-18
US61/415,136 2010-11-18
US201161510653P 2011-07-22 2011-07-22
US201161510648P 2011-07-22 2011-07-22
US201161510660P 2011-07-22 2011-07-22
US61/510,648 2011-07-22
US61/510,653 2011-07-22
US61/510,660 2011-07-22
PCT/US2011/061440 WO2012068483A1 (en) 2010-11-18 2011-11-18 Preselection of subjects for therapeutic treatment based on hypoxic status

Publications (1)

Publication Number Publication Date
CN103327976A true CN103327976A (zh) 2013-09-25

Family

ID=45217699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800653411A Pending CN103327976A (zh) 2010-11-18 2011-11-18 基于缺氧状态预选受试者以用于治疗性治疗

Country Status (7)

Country Link
US (2) US20120128665A1 (https=)
EP (1) EP2640385A1 (https=)
JP (1) JP2014503499A (https=)
CN (1) CN103327976A (https=)
AU (1) AU2011329681A1 (https=)
CA (1) CA2817564A1 (https=)
WO (1) WO2012068483A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104267191A (zh) * 2014-09-09 2015-01-07 北京大学口腔医学院 口腔口咽鳞状细胞癌的生物标志物及其应用
CN105709239A (zh) * 2016-03-22 2016-06-29 山东省肿瘤医院 一种非小细胞肺癌放疗相关的HIF-1α的抑制剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
WO2013170182A1 (en) * 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2013173436A1 (en) * 2012-05-16 2013-11-21 Synta Pharmaceuticals Corp. Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
US20160022757A1 (en) * 2013-03-15 2016-01-28 Icahn School Of Medicine At Mount Sinai Therapeutic methods for treating solid tumors and related diagnostic methods
KR20160089528A (ko) * 2013-12-12 2016-07-27 더 브리검 앤드 우먼즈 하스피털, 인크. 신경퇴행성 질환의 치료
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016073669A1 (en) * 2014-11-05 2016-05-12 Vojo Vukovic Combination therapy of hsp90 inhibitory compounds with mtor inhibitors
US20190038209A1 (en) * 2016-02-01 2019-02-07 Board Of Regents, The University Of Texas System Using Spectral CT to Diagnose Thyroid Nodules
JPWO2023276768A1 (https=) * 2021-06-29 2023-01-05

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031824A1 (en) * 2006-04-04 2008-02-07 Regents Of The University Of New Mexico Swellable particles for drug delivery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250255A (en) 1977-07-11 1981-02-10 Eastman Kodak Company Assay method for isoenzyme activity
US6242208B1 (en) 1988-07-15 2001-06-05 International Reagents Corporation LDH1 assay
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
SE530596C2 (sv) 2006-10-13 2008-07-15 Mathias Karlsson Metod att fastställa syrebrist i blod från skalpen under förlossning
CA2670134A1 (en) 2006-11-21 2008-08-28 Beth Israel Deaconess Medical Center Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
US20080318241A1 (en) * 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031824A1 (en) * 2006-04-04 2008-02-07 Regents Of The University Of New Mexico Swellable particles for drug delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLGAN STEPHEN M ET AL.: "Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis", 《CLINICAL COLORECTAL CANCER》 *
ERIC VAN CUTSEM ET AL.: "hase Ⅲ trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
YANG ZHEN FAN ET AL.: "Hige doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma:dual effects on cancer cell and angiogenesis", 《MOLECULAR CNACER THERAPEUTICS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104267191A (zh) * 2014-09-09 2015-01-07 北京大学口腔医学院 口腔口咽鳞状细胞癌的生物标志物及其应用
CN104267191B (zh) * 2014-09-09 2016-03-23 北京大学口腔医学院 口腔鳞状细胞癌的生物标志物及其应用
CN105709239A (zh) * 2016-03-22 2016-06-29 山东省肿瘤医院 一种非小细胞肺癌放疗相关的HIF-1α的抑制剂

Also Published As

Publication number Publication date
JP2014503499A (ja) 2014-02-13
WO2012068483A1 (en) 2012-05-24
US20140178366A1 (en) 2014-06-26
CA2817564A1 (en) 2012-05-24
US20120128665A1 (en) 2012-05-24
AU2011329681A1 (en) 2013-05-30
EP2640385A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
CN103327976A (zh) 基于缺氧状态预选受试者以用于治疗性治疗
US20140024030A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status
JP6742391B2 (ja) 併用療法
Jin et al. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer
US20150253330A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
JP2019519519A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
KR20160085365A (ko) 암 치료를 위한 병용 요법
US20140113972A1 (en) Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
JP6900320B2 (ja) がんにおけるマイクロピノサイトーシス
US20140348819A1 (en) Methods of Treating Cancer
US20130237546A1 (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
WO2013170182A1 (en) Treating cancer with an hsp90 inhibitory compound
WO2025125679A1 (en) Improved anti-cancer treatment regimen
KR20260008112A (ko) 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법
CN121620372A (zh) Plk1抑制剂对缺氧信号传导途径的抑制作用
KR20250065332A (ko) 변형된 stk11 활성 또는 발현을 갖는 암을 치료하기 위한 hdac 억제제
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130925